Diligence memo · auto-generated · as of July 2, 2026

Sun BioPharma, Inc.

Sun BioPharma, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Sun BioPharma, Inc. operates in Biotechnology, based in PONTE VEDRA BEACH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Sun BioPharma, Inc. has raised $8.0M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.1M on 2014-01-24.

Most recent recorded round closed around 2015-09-04.

Valuation (modeled)modeled

Provath models Sun BioPharma, Inc. at approximately $52M (range $846K–$409M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.78× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era. Within the normal band (78% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 10.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.6× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 52% of Biotechnology peers (4293 compared).

Modeled value ranks above 46% of those peers.

Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..

Peoplefiled

15 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.